XM does not provide services to residents of the United States of America.
A
A

AstraZeneca

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

US natgas prices ease to 7-week low on output rise, ample storage

UPDATE 2-US natgas prices ease to 7-week low on output rise, ample storage Adds latest prices By Scott DiSavino July 3 (Reuters) - U.S. natural gas futures eased about 1% to a seven-week low on Wednesday on a rise in output so far in July and the oversupply of gas still in storage. Gas stockpiles were now about 19% above normal for this time of year.
A
N

US natgas prices hold near 7-week low ahead of storage report

US natgas prices hold near 7-week low ahead of storage report By Scott DiSavino July 3 (Reuters) - U.S. natural gas futures held near a seven-week low on Wednesday as the market waits for direction from what should be a bullish federal report expected to show last week's storage build was smaller than usual for an eighth week in a row. That lack of price movement came despite a bullish heat wave expected to linger over much of the country through at least mid--July and a bearish rise in output s
A
N

Absci gains after Morgan Stanley starts with 'overweight' rating

BUZZ-Absci gains after Morgan Stanley starts with 'overweight' rating ** Shares of Absci Corp ABSI.O rises 7.7% to $3.2 in premarket trading ** Morgan Stanley initiates coverage on the AI biologics firm with "overweight" rating and $7 price target, implying a more than twofold upside to last close ** ABSI is using its artificial intelligence and ma
A
A

A closer look at U.S. drug pricing risks

LIVE MARKETS-A closer look at U.S. drug pricing risks STOXX 600 up 0.8% Paris, Milan bourses outperform Fed rate cut bets support mood Wall St futures broadly unchanged Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com A CLOSER LOOK AT U.S.
A
A
E
N
U
E
F
I
U
G

Aptamer Group Says Agreement With AstraZeneca To Explore Optimer Vehicles For siRNA

BRIEF-Aptamer Group Says Agreement With AstraZeneca To Explore Optimer Vehicles For siRNA July 3 (Reuters) - Aptamer Group PLC APTA.L : AGREEMENT TO EXPLORE OPTIMER VEHICLES FOR SIRNA SIGNS AGREEMENT WITH ASTRAZENECA ASTRAZENECA TO PROVIDE SIRNA FOR TRIAL Source text for Eikon: ID:nRSC8869Ua Further company coverage: APTA.L
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.